

# ARE YOUR PATIENTS AT RISK FOR RSV?




**How many of your patients are aged 60 or older? Do they have medical conditions like asthma, diabetes, COPD, CHF, or advanced liver or kidney disease?** These patients need you to help them understand the importance of vaccination with mRESVIA.<sup>1-4</sup>

For patients aged 60 or older, the risk of severe RSV infection and hospitalization can be high—making protection that much more important.<sup>1,3,5-7</sup> RSV can be especially risky for older adults with comorbidities like those mentioned above.<sup>2,8</sup>

To protect against RSV, the CDC recommends vaccinating all adult patients who are aged 75 or older, as well as those who are aged 60 or older, with an increased risk of severe RSV disease.<sup>9</sup>

**0**  
treatments

**There is no treatment for an RSV infection beyond supportive care.**<sup>10,11</sup>



**mRESVIA—the only RSV protection in a ready-to-use pre-filled syringe—has a demonstrated safety profile and was proven to protect adults aged 60 or older against RSV, regardless of comorbidities or elevated frailty status.**<sup>3,12,13</sup>

mRESVIA is ready to use once thawed to room temperature.<sup>3</sup>

YOUR PATIENTS RELY ON YOU FOR GUIDANCE THEY CAN TRUST.  
TALK TO YOUR OLDER PATIENTS TO DETERMINE IF mRESVIA IS RIGHT FOR THEM.

CDC = Centers for Disease Control and Prevention; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; RSV = respiratory syncytial virus.

## INDICATION


mRESVIA® (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.

## IMPORTANT SAFETY INFORMATION

### Contraindications

Do not administer mRESVIA to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of mRESVIA

**Please see Important Safety Information throughout and click here for Full Prescribing Information.**



# RSV FAQs

Your patients aged 60 or older may not realize the risks associated with RSV. You can help them understand what's at stake. Here are some frequently asked questions and answers that can help support your recommendation for RSV vaccination with mRESVIA.

## ABOUT RSV

### What is RSV?

RSV stands for respiratory syncytial virus, a common virus that can affect your lungs and breathing passages. RSV often begins with mild cold- or flu-like symptoms, but for people aged 60 or older, infection can lead to serious conditions, like pneumonia and worsening of symptoms for those with COPD or CHF.<sup>15</sup>

### Why haven't I heard of RSV vaccination before?

In the past, RSV was more often recognized in babies and small children, so the public may have been less aware of RSV as a serious respiratory virus in older adults.<sup>7</sup> Also, adult RSV vaccines have only recently been approved so they are relatively new.<sup>3,12,13</sup> The CDC recommends vaccinating all adults aged 75 or older, as well as adults aged 60 or older with increased risk for RSV disease.<sup>9</sup>

### How severe is my risk from RSV compared to the flu or COVID-19?


An analysis of adults aged 60 or older who were hospitalized with either RSV, influenza, or COVID-19 showed that those with RSV infection were more likely to receive supplemental oxygen and admission to the ICU compared to patients with COVID-19 or influenza.<sup>14</sup> Fortunately, there are vaccines available for flu, COVID-19, and RSV.

## IMPORTANT SAFETY INFORMATION (continued)

### Warnings and Precautions

- **Management of Acute Allergic Reactions:** Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mRESVIA.
- **Syncope:** Syncope (fainting) may occur in association with administration of injectable vaccines, including mRESVIA. Procedures should be in place to avoid injury from fainting.
- **Altered Immunocompetence:** Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to mRESVIA.

**Please see Important Safety Information throughout and click here for Full Prescribing Information.**



# RSV FAQs (continued)

## ABOUT mRESVIA

**Will this vaccine give me side effects like the COVID-19 mRNA vaccine?**

In the clinical trials, most of the side effects resolved within 1 to 2 days. The most common side effects associated with mRESVIA include injection site pain, fatigue, headache, and muscle or joint pain. Overall, mRESVIA was well tolerated with side effects described as mostly mild or moderate.<sup>3\*</sup>

**This RSV vaccine is new—is it safe?**

mRESVIA has been approved by the FDA. In clinical trials, there were no serious side effects that were found to be caused only by mRESVIA.<sup>3†</sup>

**Haven't there been cases of Guillain-Barré syndrome (GBS) after RSV vaccination?**

There are no reported cases of GBS with mRESVIA.<sup>3,9</sup>

**Will this vaccine be covered by my insurance?**

mRESVIA is covered for nearly all patients aged 60 or older and is available for Medicare Part D patients at \$0.<sup>15-17‡§</sup>

**Should I talk to my doctor before I get an mRESVIA vaccine?**

It's always a good idea to talk to your doctor about any topic related to your health, including routine vaccination. You can get the mRESVIA vaccine without needing to request a prescription, or schedule an appointment to get it at another time.

\*No Grade 4 solicited local reactions were reported. With the exception of fever, no Grade 4 solicited systemic reactions were reported.<sup>3</sup>

†Serious adverse reactions (ARs) were reported at similar rates in 7.8% of the mRESVIA group and 7.9% of the placebo group.<sup>3</sup>

‡Coverage and cost may vary and are subject to change without notice. Reimbursement decisions are made by individual insurance plans.

§Per the Inflation Reduction Act.


CDC = Centers for Disease Control and Prevention; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; FDA = Food and Drug Administration.

## IMPORTANT SAFETY INFORMATION (continued)

### Adverse Reactions

In a clinical trial, the most commonly reported ( $\geq 10\%$ ) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%) and chills (11.6%).

***Please see Important Safety Information throughout and click here for Full Prescribing Information.***



**IMPORTANT SAFETY INFORMATION (continued)****Adverse Reactions (continued)**

To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or [www.vaers.hhs.gov](http://www.vaers.hhs.gov).

**Please click for [mRESVIA Full Prescribing Information](#).**

For Colorado and Connecticut price disclosure, please visit <https://modernadirect.com/wac-disclosure>

**References:** **1.** Centers for Disease Control and Prevention. Older adults are at high risk for severe RSV illness. Updated April 2024. Accessed July 9, 2024. <https://www.cdc.gov/rsv/factsheet-older-adults.pdf> **2.** Njue A, Nuabor W, Lyall M, et al. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection among high-income countries. *Open Forum Infect Dis.* 2023;10(11):ofad513. doi:10.1093/ofid/ofad513 **3.** mRESVIA Prescribing Information. ModernaTX, Inc. **4.** Centers for Disease Control and Prevention. RSV in adults. Updated July 3, 2024. Accessed July 9, 2024. [https://www.cdc.gov/rsv/older-adults?CDC\\_AAref\\_Val=https://www.cdc.gov/rsv/high-risk/older-adults.html](https://www.cdc.gov/rsv/older-adults?CDC_AAref_Val=https://www.cdc.gov/rsv/high-risk/older-adults.html) **5.** National Foundation for Infectious Diseases. Respiratory syncytial virus (RSV). Updated January 2024. Accessed May 1, 2024. <https://www.nfid.org/infectious-disease/rsv> **6.** Havers FP, Whitaker M, Melgar M, et al. Characteristics and outcomes among adults aged ≥60 years hospitalized with laboratory-confirmed respiratory syncytial virus - RSV-NET, 12 states, July 2022-June 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(40):1075-1082. doi:10.15585/mmwr.mm7240a1 **7.** Nuwer R. Hidden hospitalizations. *Nature.* 2023;621(7980):S58-S59. doi:10.1038/d41586-023-02958-y **8.** Mayo Clinic. RSV and older adults: who's at risk? Published September 19, 2023. Accessed May 1, 2024. <https://mcpres.mayoclinic.org/rsv/rsv-and-older-adults-whos-at-risk> **9.** Centers for Disease Control and Prevention. CDC updates RSV vaccination recommendation for adults. Updated June 26, 2024. Accessed July 9, 2024. <https://www.cdc.gov/media/releases/2024/s-0626-vaccination-adults.html> **10.** Malik S, Ahmad T, Muhammad K, Waheed Y. Respiratory syncytial virus infection: treatments and clinical management. *Vaccines (Basel).* 2023;11(2):491. doi:10.3390/vaccines11020491 **11.** Gatt D, Martin I, AlFouzan R, Moraes TJ. Prevention and treatment strategies for respiratory syncytial virus (RSV). *Pathogens.* 2023;12(2):154. doi:10.3390/pathogens12020154 **12.** AREXVY Prescribing Information. GlaxoSmithKline Biologics SA. **13.** ABRYSVO Product Information. Pfizer Inc. **14.** Surie D, Yuengling KA, DeCuir J, et al. Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged ≥60 years - IVY Network, 20 US States, February 2022-May 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(40):1083-1088. doi:10.15585/mmwr.mm7240a2 **15.** US Department of Health and Human Services. Inflation reduction act toolkit. Published April 3, 2024. Accessed May 1, 2024. <https://www.hhs.gov/inflation-reduction-act/toolkit/index.html> **16.** National Council on Aging. Are all vaccines fully covered by Medicare and Medicaid? Published January 5, 2024. Accessed May 1, 2024. <https://www.ncoa.org/article/medicare-and-medicaid-now-fully-cover-preventive-vaccines> **17.** Johns Hopkins Health Plans. Protect yourself from the respiratory triple threat. Updated February 5, 2024. Accessed May 1, 2024. <https://www.hopkinsmedicare.com/news/respiratory-triple-threat>



by **moderna**